Zhiwei Zheng

机构：Shantou University, Cancer Hospital of Shantou University Medical College · ORCID：0000-0002-7815-3221

发表论文 14 篇 · 总被引 57 次 · h-index 5

代表论文

• Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis (2024 · Frontiers in Public Health · 被引 12)
• Efficacy and safety of rituximab biosimilars or reference product as first‐line treatment in patients with low‐tumour‐burden follicular lymphoma: A systematic review and meta‐analysis (2022 · Journal of Clinical Pharmacy and Therapeutics · 被引 9)
• Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis (2024 · Frontiers in Pharmacology · 被引 7)
• Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis (2024 · BMJ Open · 被引 6)
• Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma (2023 · Immunotherapy · 被引 6)
• Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis (2023 · Therapeutic Advances in Medical Oncology · 被引 5)